SPRO

SMARTPROS LTD COM STK

SPRO

Delisted

SPRO was delisted on the 22nd of December, 2015.

Back to rankings

Consumer Staples Education & Training Services

Financial journalist opinion

Zacks Investment Research

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Esther P. Rajavelu - CEO, CFO, President & Treasurer Shai Biran - Corporate Participant Timothy Keutzer - Chief Operating Officer Conference Call Participants Gautam Chukka - Evercore ISI Institutional Equities, Research Division Operator Good afternoon, and welcome to Spero Therapeutics Second Quarter 202 Earnings Conference Call.

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the second quarter ended June 30, 2025, and provided a business update.

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update.

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Based on the positive results of the registrational Phase 3 PIVOT-PO study, Tebipenem is expected to be approved under the SPA in mid-2026. Spero will not bear any costs or risks since GSK, as a license partner, will take over commercialization. Approval is expected to trigger in total of $175 million in milestone payments over the next 12 months.

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

Zacks Investment Research

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) An estimated 2.9 million cases of cUTIs are treated annually in the US 1 with many cases requiring hospitalization, contributing to over $6 billion per year in healthcare costs 2 Data from the PIVOT-PO trial to be part of a planned US Food and Drug Administration (FDA) filing in 2H 2025 that Spero's development partner, GSK, intends to submit CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), including pyelonephritis, met its primary endpoint and will stop early for efficacy (NCT06059846).3 The decision follows a recommendation from an Independent Data Monitoring Committee (IDMC) that completed a pre-specified interim analysis of data from 1,690 patients enrolled in the trial.

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

Zacks Investment Research

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

See News Rankings

Charts implemented using Lightweight Charts™